NCT05033743View on ClinicalTrials.gov

Suppressive Antibacterial Therapy With Once-Weekly Secnidazole Granules to Prevent Recurrent Bacterial Vaginosis; A Pilot Study

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 9, 2021

Primary Completion Date

October 7, 2022

Study Completion Date

October 7, 2022

Conditions
Recurrent Bacterial Vaginosis
Interventions
DRUG

Secnidazole 2 GM Oral Granules

Once weekly 2g oral secnidazole for 18 weeks

Trial Locations (1)

46202

Indiana University Hospital - Coleman Center for Women, Indianapolis

Sponsors
All Listed Sponsors
collaborator

Lupin Pharmaceuticals, Inc.

INDUSTRY

lead

Indiana University

OTHER

NCT05033743 - Suppressive Antibacterial Therapy With Once-Weekly Secnidazole Granules to Prevent Recurrent Bacterial Vaginosis; A Pilot Study | Biotech Hunter | Biotech Hunter